Emavusertib (phosphate)

• Description :

  Emavusertib phosphate (CA-4948 phosphate) is the phosphate salt form of Emavusertib (HY-135317) . Emavusertib phosphate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib phosphate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib phosphate exhibits antitumor activity in mouse model[1][2][3].

• Product Name Alternative :

  CA-4948 (phosphate)

• UNSPSC :

  12352005

• Target :

  Apoptosis; FLT3; IRAK; MyD88; NF-κB

• Related Pathways :

  Apoptosis; Immunology/Inflammation; NF-κB; Protein Tyrosine Kinase/RTK

• Field of Research :

  Cancer; Inflammation/Immunology

• Smiles :

  O=P(O)(O)O.O=C(C1=COC(C2=CC=NC(C)=C2)=N1)NC3=C(N4CC[C@H](C4)O)N=C5C(OC(N6CCOCC6)=N5)=C3

• Molecular Formula :

  C24H28N7O9P

• Molecular Weight :

  589.49

• References & Citations :

  [1]Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.|[2]Guidetti F, et al. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. J Clin Med. 2023 Jan 4;12 (2) :399. |[3]Parrondo RD, et al. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023 Oct 26;14:1239082.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [2376399-38-9]